Effects of TSH-suppressive therapy on cardiac morphology and function: Beneficial effects of the addition of β-blockade on diastolic dysfunction

European Journal of Endocrinology

Volumn 150, Issue 5, 2004, Pages 655-661

  Gullu, Sevim ^a   Altuntas, Fevzi ^a   Dincer, Irem ^a   Erol, Cetin ^a   Kamel, Nuri ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; LEVOTHYROXINE; LEVOTIRON; LIOTHYRONINE; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLE; DRUG MECHANISM; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE; FEMALE; FUNCTIONAL MORPHOLOGY; HEART DISEASE; HEART FUNCTION; HEART INDEX; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE RELAXATION; HUMAN; LONG TERM CARE; NODULAR GOITER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VOLUMETRY; WORKLOAD;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ATENOLOL; BLOOD FLOW VELOCITY; CORONARY CIRCULATION; DIASTOLE; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEART; HEART RATE; HUMANS; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHYSICAL ENDURANCE; STROKE VOLUME; SYSTOLE; THYROTROPIN; THYROXINE;

EID: 2942736865     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500655     Document Type: Article

References (33)

1. Biondi B, Palmieri EA, Lombardi G & Fazio S. Effects of thyroid hormone on cardiac function: the relative importance of rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 2002 87 968-974.
2. Klein I & Ojamaa K. Thyroid hormone and the cardiovascular system. New England Journal of Medicine 2001 344 501-509.
3. Klein I & Ojamaa K. Thyroid hormone - targeting the heart. Endocrinology 2001 142 11-12.
4. Toft AD & Boon NA. Thyroid disease and the heart. Heart 2000 84 455-460.
5. Fadel BM, Ellahham S, Ringel MD, Lindsay J Jr, Wartofsky L & Burman KD. Hyperthyroid heart disease. Clinical Cardiology 2000 23 402-408.
6. Klein I. Thyroid hormone and the cardiovascular system. American Journal of Medicine 1990 88 631-637.
7. Ladenson PW. Recognition and management of cardiovascular disease related to thyroid dysfunction. American Journal of Medicine 1990 88 638-641.
8. Dillmann WH. Biomedical basis of thyroid hormone action in the heart. American Journal of Medicine 1990 88 626-630.
9. Polikar R, Burger AG, Scherrer U & Nicod P. The thyroid and the heart. Circulation 1993 87 1435-1441.
10. Mandel SJ, Brent GA & Larsen PR. Levothyroxine therapy in patients with thyroid disease. Annals of Internal Medicine 1993 119 492-502.
11. Gharib H & Mazzaferri EL. Thyroxine suppressive therapy in patients with nodular thyroid disease. Annals of Internal Medicine 1998 128 386-394.
12. Ross DS. Subclinical hyperthyroidism: possible danger of overzealous thyroxine replacement therapy. Mayo Clinics Proceedings 1988 63 1223-1229.
13. Banovac K, Papic M, Bilsker MS, Zakarija M & McKenzie JM. Evidence of hyperthyroidism in apparently euthyroid patients treated with levothyroxine. Archives of Internal Medicine 1989 149 809-812.
14. Biondi B, Fazio S, Carella C, Amato G, Cittadini A, Lupoli G et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. Journal of Clinical Endocrinology and Metabolism 1993 77 334-338.
15. Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A et al. Control of adrenergic overactivity by β-blockade improves the quality of life in patients receiving long-term suppressive therapy with levothyroxine. Journal of Clinical Endocrinology and Metabolism 1994 78 1028-1033.
16. Fazio S, Biondi B, Carella C, Sabatini D, Cittadini A, Panza N et al. Diastolic dysfunction in patients on thyrotropin-suppressive therapy with levothyroxine: beneficial effect of β-blockade. Journal of Clinical Endocrinology and Metabolism 1995 80 2222-2226.
17. Biondi B, Fazio S, Cuocolo A, Sabatini D, Nicolai E, Lombardi G et al. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. Journal of Clinical Endocrinology and Metabolism 1996 81 4224-4228.
18. Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L et al. Cardiac function, physical exercise capacity and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual tailoring. Journal of Clinical Endocrinology and Metabolism 2000 85 159-164.
19. Shapiro LE, Sievert R, Ong L, Ocampo EL, Chance RA, Lee M et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. Journal of Clinical Endocrinology and Metabolism 1997 82 2592-2595.
20. Bonow RO & Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Annals of Internal Medicine 1992 117 502-509.
21. van Kraaij DJ, van Pol PE, Ruiters AW, de Swart JB, Lips DJ, Lencer N et al. Diagnosing diastolic heart failure. European Journal of Heart Failure 2002 4 419-430.
22. Smiseth OA. Assessment of ventricular diastolic function. Canadian Journal of Cardiology 2001 17 1167-1176.
23. Phillips RA & Diamond JA. Diastolic function in hypertension. Current Cardiology Reports 2001 3 485-497.
24. Maniu CV & Redfield MM. Diastolic dysfunction: insights into pathophysiology and pharmacotherapy. Expert Opinion on Pharmacotherapy 2001 2 997-1008.
25. de Simone G & Palmieri V. Diastolic dysfunction in arterial hypertension. Journal of Clinical Hypertension 2001 3 22-27.
26. Sahn DJ, DeMaria AN, Kisslo J & Weymen AE. Recommendation regarding quantitation in M-Mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978 5 1072-1083.
27. Devereux RB & Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation 1977 55 1441-1446.
28. Minz G, Pizzarello R & Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. Journal of Clinical Endocrinology and Metabolism 1991 73 146-150.
29. Olson BR, Klein I, Benner R, Burdett R, Trzepacz P & Levey GS. Hyperthyroid myopathy and response to treatment. Thyroid 1991 1 137-141.
30. Papini E, Petrucci L, Guglielmi R, Panunzi C, Rinaldi R, Bacci V et al. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. Journal of Clinical Endocrinology and Metabolism 1998 83 780-783.
31. Gullu S, Gurses MA, Baskal N, Uysal AR, Kamel AN & Erdogan G. Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter. Endocrine Jounal 1999 46 221-226.
32. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F & DeGroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 1994 79 98-105.
33. Kamel N, Gullu S, Dagci Ilgin S, Corapcioglu D, Tonyukuk Cesur V, Uysal AR et al. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases. Thyroid 1999 9 1245-1248.